Cetera Advisor Networks’s Tvardi Therapeutics TVRD Stock Holding History

Cetera Advisor Networks’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-333	Closed	-$20.1K	–	2885
2023 Q3	$20.1K	Buy	333 +9	+3%	+$844	﹤0.01%	2668
2023 Q2	$33K	Buy	324 +27	+9%	+$3.72K	﹤0.01%	2539
2023 Q1	$52.4K	Buy	297 +6	+2%	+$2.01K	﹤0.01%	2490
2022 Q4	$112K	Sell	291 -6	-2%	-$2.28K	﹤0.01%	2365
2022 Q3	$100K	Buy	297 +15	+5%	+$5.43K	﹤0.01%	1964
2022 Q2	$93K	Buy	+282	New	+$98.9K	﹤0.01%	1964
2020 Q3	–	Sell	-59	Closed	-$36K	–	3101
2020 Q2	$36K	Buy	+59	New	+$32.6K	﹤0.01%	2094
2018 Q1	–	Sell	-293	Closed	-$125K	–	997
2017 Q4	$125K	Buy	+293	New	+$134K	0.01%	958

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cetera Advisor Networks's TVRD Position: Q4 2023 in Review

Cetera Advisor Networks sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 333 shares — an estimated $20.1K sold.

Cetera Advisor Networks first reported a position in TVRD in Q4 2017 and held it in 8 quarters. The position peaked at $125K in Q4 2017. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

Cetera Advisor Networks reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
Cetera Advisor Networks sold 333 Tvardi Therapeutics shares in Q4 2023, an estimated $20.1K.
Cetera Advisor Networks first reported a position in Tvardi Therapeutics in Q4 2017 and held it in 8 quarters.
Cetera Advisor Networks's Tvardi Therapeutics position peaked at $125K in Q4 2017.
109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Cetera Advisor Networks's 13F filing for Q4 2023, filed 13 Feb 2024.